Breaking News, Collaborations & Alliances

Selexis Inks Agreement With Sanofi

Will develop cell lines for three Sanofi biologics programs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Selexis SA has entered three service agreements with Sanofi through which Selexis will develop research cell banks using its SUREtechnology Platform. Under the three agreements, Selexis will develop: a cell line for a naked antibody; a new cell line for a bispecific antibody; and a new cell line for the expression of a complex recombinant vaccine protein. “Our SUREtechnology Platform provides an option that biopharmaceutical companies may consider for developing both biologics and vaccine ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters